ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1178

Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis

Genna Braverman1, Sabahat Bokhari2, Kazato Ito3, Joan Bathon2 and Jon Giles4, 1NY Presbyterian - Columbia University Irving Medical Center, New York, NY, 2Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, 3Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 4Columbia University, New York, NY

Meeting: ACR Convergence 2020

Keywords: Atherosclerosis, Cardiovascular, Disability, exercise, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The 400 meter timed walk test has been studied as a simple summary measure of fitness that is predictive of mobility limitation and incident cardiovascular disease (CVD) events in older individuals. However, it has not been studied in the context of CVD in RA, a disease associated with physical disability, a heightened risk of atherosclerosis and myocardial dysfunction.

Methods: RA participants in a study of subclinical CVD underwent cardiac computed tomography (CT) for assessment of coronary artery calcification (CAC), 18-flourodeoxyglucose (FDG) positron emission tomography (PET) CT for assessment of aortic FDG uptake (a measure of atherosclerotic plaque inflammation) and myocardial FDG uptake (a measure of myocarditis), stressed N-13 ammonia PET for assessment of coronary microvascular dysfunction (CMD) and 3D echocardiography for assessment of left ventricular structure and function. Patients also underwent the 400m timed walk test. Generalized linear models were used to model walking endurance (i.e. total walking time) and walking speed with CVD outcomes, adjusting for potential confounders. We explored whether self-reported disability—as captured by the Health Assessment Questionnaire (HAQ)—recreated the same associations as the walk test.

Results: A total of 119 RA patients were studied [mean age=54 ± 13 years; 82% female; 74% seropositive for RF or anti-CCP; median RA duration=7 years; median DAS28-CRP=3.9]. Among these, 103 (87%) completed the walk test. Nine (8%) started but could not complete the walk, and 7 (6%) did not initiate the test. Among completers, those in the slowest time tertile were significantly older, had higher BMIs and more traditional CVD risk factors. RA duration, DAS28-CRP, tender joint count, CRP and HAQ scores were significantly higher in the slower tertile compared with the faster, but DMARD treatment did not differ. Slower completion time was associated with significantly higher CAC, aortic FDG uptake, left ventricular mass index and echocardiographic measures consistent with diastolic dysfunction (i.e. higher E/e’ ratio) (Figure). Although ejection fraction did not differ according to walk time, global longitudinal strain was worst in the slower group (Figure). Neither walk time nor walk speed was associated with myocardial FDG uptake or CMD. Modeling HAQ for walk time and walk speed did not recreate the associations. However, modeling potential confounders eliminated the associations of walk time and walk speed with all of the CVD outcomes except walk time with aortic FDG uptake, which remained significantly associated with slower walk time after adjustment for relevant confounders.

Conclusion: Although not independently associated with all CVD outcomes, walking endurance and speed is a potential summary measure of CVD risk that is a composite of multiple traditional and inflammatory risk factors for atherosclerosis and myocardial dysfunction in RA.

Association of 400m Walk Completion Time with Coronary Calcium, Arterial Inflammation, and Myocardial Structure and Function


Disclosure: G. Braverman, None; S. Bokhari, None; K. Ito, None; J. Bathon, None; J. Giles, AbbVie, 5, Bristol-Myers Squibb, 5, Eli Lilly, 5, Gilead, 5, Pfizer, 2.

To cite this abstract in AMA style:

Braverman G, Bokhari S, Ito K, Bathon J, Giles J. Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/associations-of-walking-endurance-and-speed-with-multiple-measures-of-subclinical-cardiovascular-disease-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-walking-endurance-and-speed-with-multiple-measures-of-subclinical-cardiovascular-disease-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology